Charles Schwab’s Immunic IMUX Stock Holding History

Charles Schwab’s Portfolio IMUX Stock Details IMUX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-8,500	Closed	-$94.3K	–	3493
2026 Q1	$94.3K	Buy	8,500 +6,000	+240%	+$53.7K	﹤0.01%	3390
2025 Q4	$13.3K	Hold	2,500	–	–	﹤0.01%	3454
2025 Q3	$22K	Hold	2,500	–	–	﹤0.01%	3454
2025 Q2	$17.4K	Hold	2,500	–	–	﹤0.01%	3491
2025 Q1	$27.3K	Hold	2,500	–	–	﹤0.01%	3445
2024 Q4	$25K	Hold	2,500	–	–	﹤0.01%	3480
2024 Q3	$41.3K	Sell	2,500 -10	-0.4%	-$142	﹤0.01%	3431
2024 Q2	$27.9K	Buy	2,510 +10	+0.4%	+$124	﹤0.01%	3569
2024 Q1	$33K	Hold	2,500	–	–	﹤0.01%	3399
2023 Q4	$37.5K	Hold	2,500	–	–	﹤0.01%	3434
2023 Q3	$36.8K	Hold	2,500	–	–	﹤0.01%	3434
2023 Q2	$62.8K	Hold	2,500	–	–	﹤0.01%	3389
2023 Q1	$37.3K	Buy	+2,500	New	+$46.4K	﹤0.01%	3400
2022 Q2	–	Sell	-4,889	Closed	-$553K	–	3593
2022 Q1	$553K	Hold	4,889	–	–	﹤0.01%	3069
2021 Q4	$468K	Buy	4,889 +345	+8%	+$31.1K	﹤0.01%	3167
2021 Q3	$403K	Buy	4,544 +598	+15%	+$58.9K	﹤0.01%	3205
2021 Q2	$484K	Buy	3,946 +2,134	+118%	+$295K	﹤0.01%	3177
2021 Q1	$289K	Hold	1,812	–	–	﹤0.01%	3253
2020 Q4	$278K	Hold	1,812	–	–	﹤0.01%	3189
2020 Q3	$337K	Buy	+1,812	New	+$297K	﹤0.01%	2993
2019 Q2	–	Sell	-142	Closed	-$12K	–	3242
2019 Q1	$12K	Hold	142	–	–	﹤0.01%	3191
2018 Q4	$11K	Hold	142	–	–	﹤0.01%	3144
2018 Q3	$16K	Hold	142	–	–	﹤0.01%	3132
2018 Q2	$388K	Buy	+142	New	+$328K	﹤0.01%	2877
2017 Q2	–	Sell	-90	Closed	-$144K	–	3117
2017 Q1	$144K	Hold	90	–	–	﹤0.01%	2976
2016 Q4	$156K	Hold	90	–	–	﹤0.01%	3003
2016 Q3	$220K	Hold	90	–	–	﹤0.01%	2896
2016 Q2	$223K	Hold	90	–	–	﹤0.01%	2896
2016 Q1	$326K	Hold	90	–	–	﹤0.01%	2738
2015 Q4	$413K	Buy	90 +32	+55%	+$104K	﹤0.01%	2731
2015 Q3	$95K	Hold	58	–	–	﹤0.01%	3039
2015 Q2	$493K	Buy	+58	New	+$553K	﹤0.01%	2678
2014 Q3	–	Sell	-19	Closed	-$208K	–	3075
2014 Q2	$208K	Buy	+19	New	+$133K	﹤0.01%	2990

Other funds holding IMUX

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JHC

Jones Hill Capital New York $470M AUM

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Charles Schwab's IMUX Position: Q2 2026 in Review

Charles Schwab sold out of Immunic (IMUX) in Q2 2026, closing a stake of 8,500 shares — an estimated $94.3K sold.

Charles Schwab first reported a position in IMUX in Q2 2014 and held it in 33 quarters. The position peaked at $553K in Q1 2022. 55 funds tracked by Wall St. Rank hold IMUX as of Q2 2026.

Charles Schwab reported no remaining Immunic position as of Q2 2026 after selling out during the quarter.
Charles Schwab sold 8,500 Immunic shares in Q2 2026, an estimated $94.3K.
Charles Schwab first reported a position in Immunic in Q2 2014 and held it in 33 quarters.
Charles Schwab's Immunic position peaked at $553K in Q1 2022.
55 funds tracked by Wall St. Rank held Immunic as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.